arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Orchestra BioMed Holdings, Inc.

OBIO
$5.92 ▼ -0.30 (-4.90%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
25 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Orchestra BioMed Holdings, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $377.8M
Dividend Yield
Revenue Growth -89.5%
Op. Margin None
ROIC None
FCF / Share $-0.31
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$88.00K
↓ -89.5%
Net Income Profit after all expenses
$-20.69M
↓ -10.3%
FCF / Share Free cash flow per share
$-0.31
↑ +13.9%
Long-Term Debt Long-term obligations
$15.00M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 25 quarters